Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT02065622 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02065622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02065622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
March 27, 2014
Completion date
November 11, 2019
Enrollment
952 (actual)
Sites
173

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)